Guardian Partners Inc. Sells 3,151 Shares of Danaher Corporation $DHR

Key Points

• Guardian Partners Inc. reduced its stake in Danaher Corporation by 17.8% during the first quarter, leaving the firm with 14,573 shares worth approximately $2.86 million.
• Following recent transactions by large investors, a total of 79.05% of Danaher’s stock is now owned by institutional investors.
• Danaher announced a positive quarterly earnings report, exceeding estimates with earnings of $1.80 EPS and revenues of $5.94 billion, indicating a 3.4% increase in revenue year-over-year.

Guardian Partners Inc. trimmed its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 17.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,573 shares of the conglomerate's stock after selling 3,151 shares during the quarter. Guardian Partners Inc.'s holdings in Danaher were worth $2,861,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Heck Capital Advisors LLC acquired a new stake in shares of Danaher during the 4th quarter valued at about $27,000. GHP Investment Advisors Inc. lifted its holdings in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares during the last quarter. Sierra Ocean LLC lifted its holdings in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in Danaher in the 1st quarter worth approximately $31,000. Finally, Dunhill Financial LLC lifted its holdings in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after purchasing an additional 67 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Royal Bank Of Canada set a $241.00 target price on Danaher in a report on Tuesday, September 2nd. UBS Group reduced their target price on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Wells Fargo & Company reduced their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Guggenheim restated a "buy" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Finally, Barclays restated an "overweight" rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $246.35.

Danaher Stock Performance

NYSE DHR traded up $2.64 during trading on Thursday, hitting $195.23. The company's stock had a trading volume of 3,425,999 shares, compared to its average volume of 4,141,844. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average price of $201.62 and a 200 day moving average price of $199.15. The firm has a market cap of $139.79 billion, a P/E ratio of 41.54, a price-to-earnings-growth ratio of 2.71 and a beta of 0.75. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's payout ratio is currently 27.23%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.